[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593730":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":26,"locations":36,"responsibleParty":53,"collaborators":20,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":20,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":20,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":20,"overallStatus":39,"whyStopped":20,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"A-IST","EXPERIMENTAL","Porcine-ATG : 15 mg\u002Fkg\u002Fday IV ×5 days. Cyclosporine : 3-5 mg\u002Fkg\u002Fday (adjusted to trough 100-200 μg\u002FL). Hetrombopag: 15 mg daily.",[13],"Drug: Dose-attenuated IST and Hetrombopag",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Dose-attenuated IST and Hetrombopag","Porcine-ATG : 15 mg\u002Fkg\u002Fday IV ×5 days. Cyclosporine : 3-5 mg\u002Fkg\u002Fday (adjusted to trough 100-200 μg\u002FL). Hetrombopag: 15 mg daily for 24weeks.",[9],null,[22],{"name":23,"affiliation":24,"role":25},"Jun Shi, PhD","Institute of Hematology & Blood Diseases Hospital, CAMS","PRINCIPAL_INVESTIGATOR",[27,32],{"name":28,"role":29,"phone":30,"phoneExt":20,"email":31},"Jianping Li, MD","CONTACT","+8613820961539","lijianping@ihcams.ac.cn",{"name":33,"role":29,"phone":34,"phoneExt":20,"email":35},"Jingyu Zhao, MPH","+8613752253515","zhaojingyu@ihcams.ac.cn",[37],{"facility":38,"status":39,"city":40,"state":41,"zip":20,"country":42,"countryCode":43,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"Red Blood Cell Diseases Center","RECRUITING","Tianjin","Tianjin Municipality","China","CN",{"type":45,"coordinates":46},"Point",[47,48],117.17667,39.14222,{"lat":48,"lon":47},[51],{"name":28,"role":29,"phone":52,"phoneExt":20,"email":31},"13820961539",{"type":54,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100593730","phase-2-dose-attenuated-ist-and-hetrombopag-in-elderly-65-years-patients-with-severe-aplastic-anemia-100593730",false,"NCT07010237","Dose-attenuated IST and Hetrombopag in Elderly (≥65 Years) Patients With Severe Aplastic Anemia","Dose-attenuated IST and Hetrombopag in the Treatment of Elderly (≥65 Years) Patients With Very Severe\u002FSevere Aplastic Anemia: A Single-Center, Single-Arm, Phase IIB Clinical Study on Efficacy and Safety","Inclusion Criteria:\n\n* Clinical diagnosis of VSAA\u002FSAA.\n* Age ≥65 years.\n* Completion of all screening assessments.\n* Must be able to swallow tablets.\n* Signed informed consent (by patient or legal guardian if patient is incapacitated).\n\nExclusion Criteria:\n\n* Clonal cytogenetic abnormalities (excluding isolated -Y or +8).\n* Prior treatment with ATG\u002Fhigh-dose cyclophosphamide.\n* Prior cyclosporine\u002Ftacrolimus use \\>12 months.\n* Prior TPO-RA therapy \\>3 months.\n* Uncontrolled malignancies or conditions contraindicating ATG.\n* Severe organ dysfunction (e.g., creatinine ≥177 μmol\u002FL).\n* Investigator judgment of unsuitability.","ALL","65 Years",{"count":65,"type":66},65,"ESTIMATED","INTERVENTIONAL",[69],"PHASE2","This is a prospetive,Single-Center, Single-Arm, Phase IIB Clinical Study.This study aims to evaluate the efficacy and safety of dose-attenuated IST combined with Hetrombopag in elderly patients (≥65 years) with VSAA\u002FSAA.",[72,73,74],"Sever Aplastic Anaemia","Elderly (People Aged 65 or More)","Immunosuppressive Treatment","2025-06-05",{"date":77,"type":78},"2025-06-08","ACTUAL",{"date":80,"type":78},"2025-02-01",{"date":82,"type":66},"2029-07-01",{"name":5,"class":6},1]